BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27226207)

  • 1. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    Lim D; Ngeow J
    Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    Lee JM; Ledermann JA; Kohn EC
    Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors: Synthetic lethality in the clinic.
    Lord CJ; Ashworth A
    Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in Prostate Cancer.
    Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
    Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of PARP: Number crunching and structure gazing.
    Rudolph J; Jung K; Luger K
    Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2121979119. PubMed ID: 35259019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    Shao N; Shi Y; Yu L; Ye R; Shan Z; Zhang Z; Zhang Y; Lin Y
    Int J Biol Sci; 2019; 15(5):962-972. PubMed ID: 31182917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.